Public Company News

ASX listed Analytica has received approval from the powerful US Food and Drug Administration to sell their unique “PeriCoach” incontinence medical device without the need for a prescription in the USA. The PeriCoach is a proprietary medical device developed by Analytica to assist women to exercise their pelvic floor muscles in order to reduce or eliminate urinary incontinence.

ASX listed nano-satellite developer Sky and Space Global has successfully applied to register their own frequency spectrum with the United Nations’ “International Telecommunications Union”. The company says registering its own frequency spectrum is a crucial element to cretaing their own nano-satellite based affordable global telecomminications network. 

The recently released feasibility study into Neometals' patented "Eli' process that downstream processes Lithium, shows that for a $158m capital outlay, the project will return a wave of cash averaging $82m a year before tax every year for the next 20 years. It shows a net present value of AUD$638m which equates to around $1.14 a share on a fully dispersed basis. 

Anti cancer specialist drug developer Pharmaust, has successfully altered the taste of their promising new anti-cancer drug known as Monepantel to make it taste better on the eve of a new trial of the drug in dogs. The trial will commence immediately at The University of Cambridge who were responsible for inventing the jet engine and identifying the structure of DNA.

There’s nothing quite like confirmation that the drill rig has been booked for a maiden drilling campaign to get the gold bulls sniffing around. It becomes even more tempting for the bulls when the ground to be drill tested sits just 35km along trend from a nearby project that just produced a 63m intersection grading 2.2 grams per tonne gold and 0.19% copper.

After posting a stellar 242% year on year revenue increase in FY 16, ASX listed financial payments player Stargroup, has given its strongest hint yet that FY17 might be its maiden dividend year. The company’s growth seems unstoppable after it produced yet another record revenue result during the June quarter, its 10th record quarter in a row. 

With the Lithium boom well and truly captivating the market right now, Neometals have kicked the ball out of the park with a 160% upgrade to their Lithium resource at the Mt Marion project near Coolgardie. The resource is now the third biggest in the world at 60.5m tonnes grading 1.36% Lithium whereas it was previously sitting at just 23.24m tonnes grading 1.39%.

Terrain Minerals continue to make good use of historic exploration data to zero in on interesting targets. A recent review of historic data at the company’s Gimlet project, which adjoins Mt Ridley’s project in the Fraser Range, has unearthed an interesting gold target that looks to have never been properly tested which shows gold mineralization from 15PPB to 30PPB.

In the Lithium business it can be very profitable to own a mine, however, turning that Lithium into battery grade chemicals, commonly known as downstream processing, can be even more lucrative. Market darling Pilbara Minerals have given a hint of their medium term strategy after signing an MOU to move into the Lithium downstream processing business with the Chinese. 

Blackham Resources have identified a new source of high grade gold accessible from their existing underground infrastructure just 30m away at the Matilda Gold project in Wiluna. Latest results include 3.47 grams per tonne gold from 104m deep, 6m @ 8.99 g/t from 119m, 19m @ 6.71 g/t from 128m, 18m @ 4.88 g/t from 181m and 5m @ 10.8 g /t from the 134m mark.

MGC Pharmaceuticals have done what few other medical cannabis companies have managed to do – make money.The company received first revenues from its “MGC Derma” medical cannabis based line of anti-ageing cosmetics this week from their Californian distributor who has committed to buy 1.2m Euro's worth of product in the first year. 

ASX listed biotech PharmAust, is rapidly making its mark on the anti-cancer drug industry with its promising ant-cancer drug known as “MPL”. The company recently announced they would partner up with the same UK university that was first responsible for splitting the atom and the discovery of stem cells in their upcoming phase 2 trial of MPL in canines.